Overview

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Status:
Completed
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in healthy subjects, and to assess the relative bioavailability of two formulations of BMS-986195 with or without food.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Branebrutinib